MustGrow Achieves 100% Economical Control Of Panama Disease, Moves To Field Trials
MustGrow Biologics (CSE: MGRO) has seen further validation of its proprietary mustard derived biopesticide following further laboratory results. The latest data sets released by the firm have revealed that 100% control of Fusarium wilt TR4, also known as Panama Disease, has been achieved at economical levels of biopesticide application.
The latest results were conducted by a separate third-party independent lab than was utilized for the initial rounds of laboratory testing in Colombia. The additional lab was utilized as a means of providing further validation for the study.
Results have determined that 100% control of Panama Disease has been achieved with application rates as low as 5 gallons per acre, while also providing confirmation of economical rates in the laboratory. Following the success exhibited in the lab setting, the company is moving straight to field study trials to determine how effective the biopesticide is in the real world.
Economical proficiency was demonstrated if extrapolated to a plantation field scenario, with 100% control being achieved over a 3 day testing period. The control samples meanwhile saw the disease continue to grow in similar settings without the application of the biopesticide.
The strong results posed by the formulation, which no other compound is believed to have achieved, is now being pursued as a potential fast-track registration in Colombia. Work here is also to serve as a beachhead for other leading banana producing countries.
MustGrow Biologics last traded at $1.70 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.